

Common HIV drugs available in Canada for adults

Number of tablets or capsules Number of injections Number of times per day Take with food Take on an empty stomach

Brand name (generic name)	Common dosage		Dosage schedule	Food requirements
Complete fixed-dose combination treatment				
Atripla (efavirenz + emtricitabine + tenofovir disoproxil fumarate)	600 mg / 200 mg / 300 mg			
Apo-Efavirenz/Emtricitabine/Tenofovir (efavirenz + emtricitabine + tenofovir disoproxil fumarate)	600 mg / 200 mg / 300 mg			
Mylan-Efavirenz/Emtricitabine/Tenofovir (efavirenz + emtricitabine + tenofovir disoproxil fumarate)	600 mg / 200 mg / 300 mg			
Teva-Efavirenz/Emtricitabine/Tenofovir (efavirenz + emtricitabine + tenofovir disoproxil fumarate)	600 mg / 200 mg / 300 mg			
Biktarvy (bictegravir + tenofovir alafenamide + emtricitabine)	50 mg / 25 mg / 200 mg			
Complera (tenofovir disoproxil fumarate + emtricitabine + rilpivirine)	300 mg / 200 mg / 25 mg			
Delstrigo (doravirine + lamivudine + tenofovir disoproxil fumarate)	100 mg / 300 mg / 300 mg			
Dovato (dolutegravir + lamivudine)	50 mg / 300 mg			
Genvoya (elvitegravir + cobicistat + tenofovir alafenamide + emtricitabine)	150 mg / 150 mg / 10 mg / 200 mg			
Juluca (dolutegravir + rilpivirine)	50 mg / 25 mg			
Odefsey (rilpivirine + tenofovir alafenamide + emtricitabine)	25 mg / 25 mg / 200 mg			
Stribild (elvitegravir + cobicistat + tenofovir disoproxil fumarate + emtricitabine)	150 mg / 150 mg / 300 mg / 200 mg			
Symtuza (darunavir + cobicistat + tenofovir alafenamide + emtricitabine)	800 mg / 150 mg / 10 mg / 200 mg			
Triumeq (dolutegravir + abacavir + lamivudine)	50 mg / 600 mg / 300 mg			

Other combination tablets				
Combivir (lamivudine + AZT)	150 mg / 300 mg			
Apo-Lamivudine/Zidovudine (lamivudine + AZT)	150 mg / 300 mg			
Auro-Lamivudine/Zidovudine (lamivudine + AZT)	150 mg / 300 mg			
Teva-Lamivudine/Zidovudine (lamivudine + AZT)	150 mg / 300 mg			
Descovy (tenofovir alafenamide + emtricitabine)	10 mg / 200 mg / 25 mg / 200 mg			
Kivexa (abacavir + lamivudine)	600 mg / 300 mg			
Apo-Abacavir/Lamivudine (abacavir + lamivudine)	600 mg / 300 mg			
Auro-Abacavir/Lamivudine (abacavir + lamivudine)	600 mg / 300 mg			
Teva-Abacavir/Lamivudine (abacavir + lamivudine)	600 mg / 300 mg			
Prezcobix (darunavir + cobicistat)	800 mg / 150 mg			
Trizivir (abacavir + lamivudine + AZT)	300 mg / 150 mg / 300 mg			
Apo-Abacavir/Lamivudine/Zidovudine (abacavir + lamivudine + AZT)	300 mg / 150 mg / 300 mg			
Truvada (emtricitabine + tenofovir disoproxil fumarate)	200 mg / 300 mg			
Apo-Emtricitabine/Tenofovir (emtricitabine + tenofovir disoproxil fumarate)	200 mg / 300 mg			
Jamp-Emtricitabine/Tenofovir (emtricitabine + tenofovir disoproxil fumarate)	200 mg / 300 mg			
Mint-Emtricitabine/Tenofovir (emtricitabine + tenofovir disoproxil fumarate)	200 mg / 300 mg			
Mylan-Emtricitabine/Tenofovir Disoproxil (emtricitabine + tenofovir disoproxil fumarate)	200 mg / 300 mg			
PMS-Emtricitabine/Tenofovir (emtricitabine + tenofovir disoproxil fumarate)	200 mg / 300 mg			
Teva-Emtricitabine/Tenofovir (emtricitabine + tenofovir disoproxil fumarate)	200 mg / 300 mg			

Brand name (generic name)	Common dosage		Dosage schedule	Food requirements
Fusion inhibitor				
Fuzeon (enfuvirtide for injection)	90 mg	White powder in glass vial		
Long-acting injectable treatment				
Cabenuva (cabotegravir + rilpivirine)	600 mg / 900 mg (injection) initiation dose		Initiation: once a month (months 1 and 2) Maintenance: once every 2 months (month 4 onwards)	
Sunlenca (lenacapavir)	300 mg (oral) initiation dose 463.5 mg (injection) initiation dose 463.5 mg (injection) maintenance dose	Injectable: Clear, yellow to brown liquid in a clear glass vial	Initiation: 2 tablets on days 1 and 2 1 tablet on day 8 2 injections on day 15 Maintenance: 2 injections once every 6 months (26 weeks)	
Vocabria** (cabotegravir)	30 mg			

Integrase inhibitors				
Isentress (raltegravir)	400 mg			
Isentress HD (raltegravir)	600 mg			
Tivicay (dolutegravir)	50 mg			

Protease inhibitors				
Aptivus++ (tipranavir)	250 mg	Pink capsule, labelled "TPV 250"		
Kaletra* (lopinavir + ritonavir)	200 mg / 50 mg			
Norvir*+ (ritonavir)	100 mg			
Prezista*++ (darunavir)	800 mg 600 mg			
Apo-Darunavir++ (darunavir)	800 mg 600 mg			
Auro-Darunavir++ (darunavir)	800 mg 600 mg			
Reyataz++ (atazanavir)	300 mg 200 mg			
Mylan-Atazanavir++ (atazanavir)	300 mg 200 mg			
Teva-Atazanavir++ (atazanavir)	300 mg 200 mg			

Co-receptor inhibitor				
Celsentri (maraviroc)	300 mg 150 mg			

Attachment inhibitor				
Rukobia (fostemsavir)	600 mg			

Brand name (generic name)	Common dosage		Dosage schedule	Food requirements
Nukes (nucleoside and nucleotide analogues, or NRTIs)				
3TC* (lamivudine)	300 mg 150 mg			
Apo-Lamivudine (lamivudine)	300 mg 150 mg			
Retrovir* (AZT)	100 mg			
Apo-Zidovudine (AZT)	100 mg			
Viread (tenofovir disoproxil fumarate)	300 mg			
Apo-Tenofovir (tenofovir disoproxil fumarate)	300 mg			
Auro-Tenofovir (tenofovir disoproxil fumarate)	300 mg			
Mylan-Tenofovir Disoproxil (tenofovir disoproxil fumarate)	300 mg			
Teva-Tenofovir (tenofovir disoproxil fumarate)	300 mg			
Ziagen* (abacavir)	300 mg			
Apo-Abacavir (abacavir)	300 mg			
Mint-Abacavir (abacavir)	300 mg			

Non-nukes (NNRTIs)				
Eduvant (rilpivirine)	25 mg			
Intelece (etravirine)	100 mg 200 mg			
Pifeltro (doravirine)	100 mg			
Sustiva (efavirenz)	600 mg 200 mg			
Auro-Efavirenz (efavirenz)	600 mg			
Mylan-Efavirenz (efavirenz)	600 mg			
Teva-Efavirenz (efavirenz)	600 mg			
Auro-Nevirapine (nevirapine)	200 mg			

+ Taken as booster with other HIV drugs
++ Usually taken with ritonavir
* Also available in liquid formulation (not pictured)
** Taken with Eduvant for one month before starting Cabenuva (optional). Food requirements refer to Eduvant only. May also be taken with Eduvant if injections are delayed or missed.

NOTE
This chart lists common dosage schedules. People should always follow the dosing schedule prescribed by their doctor, which may vary from those shown here.

Acknowledgements
3TC*, Cabenuva*, Celsentri®, Combivir®, Dovato®, Juluca®, Kivexa®, Retrovir®, Tivicay®, Trizivir®, Vocabria®, Ziagen® and Rukobia® are registered trademarks and Triumeq™ is a trademark of the ViiV Healthcare group of companies. Images copyright ViiV Healthcare. Used with permission. • Images of Atripla®, Biktarvy™, Complera®, Descovy™, Genvoya™, Odefsey™, Stribild™, Truvada™, Viread™ and Sunlenca™ copyright Gilead Sciences Canada, Inc. Used with permission. • Images of Eduvant®, Intelece™, Prezcobix®, Prezista® and Symtuza™ copyright Janssen Inc. Used with permission. • Images of Delstrigo™, Isentress™, Isentress™ HD and Pifeltro™ copyright Merck Canada Inc. Used with permission. • Images of Apo-Abacavir/Lamivudine, Auro-Darunavir, Auro-Efavirenz, Auro-Lamivudine/Zidovudine and Auro-Tenofovir copyright Auro Pharma Inc. Used with permission. • Fuzeon® is a registered trademark of F. Hoffmann-La Roche AG. • Images of Mylan-Atazanavir, Mylan-Efavirenz, Mylan-Efavirenz/Emtricitabine/Tenofovir, Mylan-Emtricitabine/Tenofovir Disoproxil and Mylan-Tenofovir Disoproxil copyright Mylan Pharmaceuticals. Used with permission. • Images of Sustiva® and Reyataz® copyright Bristol-Myers Squibb. Used with permission. • Images of Apo-Abacavir/Lamivudine, Teva-Atazanavir, Teva-Efavirenz, Teva-Efavirenz/Emtricitabine/Tenofovir, Teva-Emtricitabine/Tenofovir, Teva-Lamivudine/Zidovudine and Teva-Tenofovir copyright Teva Pharmaceutical Industries Ltd. Used with permission. • Images of Kaletra® and Norvir® copyright AbbVie Inc. Used with permission. • Aptivus® is a registered trademark of Boehringer Ingelheim International GmbH, used under license. • Images of Apo-Darunavir, Apo-Efavirenz/Emtricitabine/Tenofovir, Apo-Abacavir/Lamivudine/Zidovudine, Apo-Lamivudine/Zidovudine, Apo-Abacavir/Lamivudine, Apo-Emtricitabine/Tenofovir, Apo-Lamivudine, Apo-Zidovudine, Apo-Tenofovir and Apo-Abacavir are owned and copyright of Apotex Technologies Inc. Used with permission. • Images of Mint-Abacavir and Mint-Emtricitabine/Tenofovir copyright Mint Pharmaceuticals Inc. Used with permission. • Image of Jamp-Emtricitabine/Tenofovir copyright Jamp Pharmaceutical Corporation. Used with permission. • Image of PMS-Emtricitabine/Tenofovir copyright Pharmascience Inc. Used with permission.

Disclaimer
CATIE endeavours to provide up-to-date and accurate information at the time of publication, but it should not be considered medical advice. Decisions about particular medical treatments should always be made in consultation with a qualified medical practitioner. CATIE resources may contain descriptions or depictions of sex, sexuality or drug use, with the goal of promoting public health. Any opinions expressed herein may not reflect the policies or opinions of CATIE or any partners or funders.

Production of this document has been made possible through a financial contribution from the Public Health Agency of Canada.